Safety of New Phosphate Binders for Chronic Renal Failure

Drug Safety

Volumn 26, Issue 15, 2003, Pages 1093-1115

  Loghman Adham, Mahmoud ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; 2' PHOSPHOPHLORETIN; ACETYLSALICYLIC ACID; ALUMINUM SALT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM CARBONATE PLUS MAGNESIUM CARBONATE; CITRATE CALCIUM; DIALYSIS FLUID; FERRIC AMMONIUM CITRATE; FERRIC CHLORIDE; FERRIC CITRATE; FERRIC HYDROXIDE; FERRIC POLYMALTOSE COMPLEX; FERRIHYDRITE; IRON DERIVATIVE; IRON DEXTRAN; LANTHANUM CARBONATE; LANTHANUM CHLORIDE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM SALT; MEGNEBIND; METAL HYDROXYL CARBONATE DERIVATIVE; NICERITROL; PHOSPHATE BINDING AGENT; RENAZORB B; RENAZORB H; SEVELAMER; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIRCONYL CHLORIDE;

ALUMINUM OVERLOAD; ANEMIA; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BRAIN DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIALYSIS ENCEPHALOPATHY; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BONE LEVEL; DRUG COST; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TISSUE LEVEL; DYSPEPSIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MAGNESIUM BLOOD LEVEL; METABOLIC ACIDOSIS; MORTALITY; MUSCLE CRAMP; NAUSEA; NONHUMAN; OSTEOMALACIA; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SKIN MANIFESTATION; SOFT TISSUE CALCIFICATION; THROMBOCYTOPENIA;

ALUMINUM; CALCIUM; EPOXY COMPOUNDS; HUMANS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; LANTHANUM; MAGNESIUM; PHOSPHATES; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; SAFETY;

EID: 0346249837     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326150-00003     Document Type: Review

References (205)

1. Knochel JP, Agarwal R. Hypophosphatemia and hyperphosphatemia. In: Brenner BM, editor. The Kidney. 5th ed. Philadelphia (PA); WB Saunders Company, 1996: 1086-133
2. Loghman-Adham M. Adaptation to changes in dietary phosphorus intake in health and in renal failure. J Lab Clin Med 1997; 129: 176-88
3. Slatopolsky E, Calar S, Penell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971; 50: 492-9
4. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-36
5. Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1999; 25: 663-79
6. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15 (5): 458-82
7. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-17
8. Ibels LS, Alfrey AC, Haut L, et al. Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 1978 Jan 19; 298 (3): 122-6
9. Loghman-Adham M. Role of phosphate retention in progression of renal failure. J Lab Clin Med 1993; 122: 16-26
10. Slatopolsky E, Caglar S, Gradowska L, et al. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using 'proportional reduction' of dietary phosphorus intake. Kidney Int 1972; 2: 147-51
11. Rufino M, deBonis E, Martin M, et al. Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998; 13 Suppl. 3: 65-7
12. K-DOQI Guidelines: 3. Management of protein and energy intake. Am J Kidney Dis 2000; 35 Suppl. 2: S40-1
13. Ring T, Nielsen C, Andersen SP, et al. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrol Dial Transplant 1993; 8: 341-6
14. Ring T. Update on phosphate binders. Nephrol Dial Transplant 1993; 8: 1310-1
15. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing hemodialysis. N Engl J Med 1986; 313: 157-61
16. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002; 17 Suppl. 2: 21-4
17. Velasquez FF, Altamirano E, Ramos PT. High frequency of iron bone deposits in a Mexican population with renal osteodystrophy. Nephrol Dial Transplant 1998; 13 Suppl. 3: 46-50
18. Nishii Y, Abe J, Mon T, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. Contrib Nephrol 1991; 19: 123-8
19. Martin KJ, Gonzalez EA, Gellens M, et al. 19-Nor-1-α-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32
20. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998; 95: 4040-5
21. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-24
22. Loghman-Adham M. Phosphate binders for control of phosphate retention in chronic renal failure. Pediatr Nephrol 1999; 13: 701-8
23. Gutzwiller J-P, Schneditz D, Huber AR, et al. Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant 2002; 17: 1037-44
24. Man NK, Chauveau P, Kuno T, et al. Phosphate removal during hemodialysis, hemodiafiltration, and hemofiltration: a reappraisal. ASAIO Trans 1991; 37: 463-5
25. Pogglitsch H, Petek W, Ziak E, et al. Phosphorus kinetics during haemodialysis and haemofiltration. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 461-8
26. DeSoi CA, Umans JG. Phosphate kinetics during high-flux hemodialysis. J Am Soc Nephrol 1993; 4: 1214-8
27. Maasrani M, Jaffrin MY, Fischbach M, et al. Urea, creatinine, and phosphate kinetic modeling during dialysis: application to pediatric hemodialysis. Int J Artif Organs 1995; 18: 122-9
28. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: evidence for biphasic regulation. Kidney Int 2002; 61: 655-67
29. Zucchelli P, Santoro A. Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 1987 May; 10 (3): 173-8
30. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 1399-404
31. Miller JH, Gardner PW, Heinekin F, et al. Studies of inorganic phosphate removal during acetate and bicarbonate dialysis. Proc Am Soc Artif Int Org 1983; 12: 57
32. Messa P, Gropuzzo M, Cleva M, et al. Behavior of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 1998; 13 Suppl. 6: 43-8
33. Ritz E, Schoemig M, Bommer J. Osteodystrophy in the millennium. Kidney Int 1999; 56 Suppl. 73: 94-8
34. Ramirez JA, Emmett M, White MG, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 1986; 30: 753-9
35. Jindal KK, McDougall J, Woods B, et al. A study of the basic principles determining the performance of several high-flux dialyzers. Am J Kidney Dis 1989; 14: 507-11
36. Chauveau P, Poignet J-L, Kuno T, et al. Phosphate removal rate: a comparative study of five high-flux dialysers. Nephrol Dial Transplant 1991; 6 Suppl. 2: 114-5
37. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration: a new treatment option for hyperphosphatemia in haemodialysis patients. Clin Nephrol 1999; 52: 152-9
38. Haas T, Hillion D, Dongradi G. Phosphate kinetics in dialysis patients. Nephrol Dial Transplant 1991; 6 Suppl. 2: 108-13
39. Fischbach M, Hamel G, Simeoni U, et al. Phosphate dialytic removal: enhancement of phosphate cellular clearance by biofiltration (with acetate-free buffer dialysate). Nephron 1992; 62: 155-60
40. Harris DCH, Yuill E, Chester DW. Correcting acidosis in hemodialysis: effect on phosphate clearance and calcification risk. J Am Soc Nephrol 1995; 6: 1067-612
41. Lindsay RM, Kortas C, Daily/Nocturnal Dialysis Study Group. Hemeral (daily) hemodialysis. Adv Ren Replace Ther 2001; 8: 236-49
42. Pierratos A. Daily hemodialysis: an update. Curr Opin Nephrol Hypertens 2002; 11: 165-71
43. Vos PF, Zilch O, Kooisrta MP. Clinical outcome of daily dialysis. Am J Kidney Dis 2001; 37 Suppl. 2: S99-S102
44. Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9: 859-68
45. Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14: 2835-40
46. Murer H, Hernando N, Forester L, et al. Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption (plenary lecture). Mol Membr Biol 2001; 18: 3-11
47. Loghman-Adham M, Motock GT. Use of phosphonoformic acid to induce phosphaturia in chronic renal failure in rats. Ren Fail 1996; 18: 855-66
48. Szczepanska-Konkel M, Yusufi AN, VanScoy M, et al. Phosphonocarboxylic acids as specific inhibitors of Na+-dependent transport of phosphate across renal brush border membrane. J Biol Chem 1986; 15: 6375-83
49. Jayaweera DT. Minimising the dosage-limiting toxicities of foscarnet induction therapy. Drug Saf 1997; 16 (4): 258-66
50. Peerce BE, Clarke R. A phosphorylated phloretin derivative: sythesis and effect on intestinal Na+-dependent phosphate absorption. Am J Physiol Gastrointest Liver Physiol 2002; 283: G846-55
51. Nakahama H, Nakanishi T, Uyama O, et al. Niceritrol reduces plasma lipoprotein (a) levels in patients undergoing maintenance hemodialysis. Ren Fail 1993; 15: 189-93
52. Shimoda K, Akiba T, Matsushima T, et al. Niceritrol decreases serum phosphate levels in hemodialysis patients: a randomized, double blind, crossover study [abstract]. J Am Soc Nephrol 1996; 7: S887
53. Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. Thromb Res 1985; 40: 543-53
54. Kuboyama N, Watanabe Y, Yamaguchi M, et al. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999; 14: 610-4
55. Kempson SA, Colon-Otero G, Ou SY, et al. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981; 67: 1347-60
56. Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999; 14: 1195-201
57. Jay RH, Dickson AC, Betteridge DJ. Effects of aspirin upon the flushing reaction induced by niceritrol. Br J Clin Pharmacol 1990; 29: 120-2
58. Wakusugi H, Futami T, Muso E, et al. Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient. Nephron 2000; 86: 97-8
59. Willis MR, Savory J. Aluminum and chronic renal failure: sources, absorption, transport, and toxicity. Crit Rev Clin Lab Sci 1989; 27: 59-107
60. Nolan CR, De Goes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med 1994; 87: 894-8
61. Kaye M. Oral aluminum toxicity in a non-dialyzed patient with renal failure. Clin Nephrol 1983; 20: 208-11
62. Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310: 1079-84
63. Sedman AB, Miller NL, Warady BA, et al. Aluminum loading in children with chronic renal failure. Kidney Int 1984; 26: 201-4
64. Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci 1989; 297: 9-11
65. Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in he toxicity of orally administered aluminum compounds. Kidney Int 1989; 36: 949-53
66. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38: 937-41
67. Pierides AM, Edwards WG, Callum UX, et al. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980; 18: 115-24
68. Felsenfeld AJ, Gutman RA, Llach F, et al. Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis. Am J Nephrol 1982; 2: 147-54
69. Malluche HM, Mawad H. Management of hyperphosphatemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant 2002; 17: 1170-5
70. Short AI, Winney RJ, Robson JS. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. Proc Eur Dial Transplant Assoc 1980; 17: 226-33
71. McGonigle RJS, Parson V. Aluminum-induced anemia in haemodialysis patients. Nephron 1985; 39: 1-9
72. Drücke TB, Lacour B, Touam M, et al. Effect of aluminum on hematopoiesis. Kidney Int 1986; 29 Suppl. 18: S45-8
73. Alfrey AC, Le Gendre GR, Kaekny WD. The dialysis encephalopathy syndrome: possible aluminum intoxication. N Engl J Med 1976; 294: 184-8
74. Kerr DN, Ward MK, Ellis HA, et al. Aluminum intoxication in renal disease. Ciba Found Symp 1992; 169: 123-35
75. Berlyne GM, ben-Ari J, Pest D, et al. Hyperaluminaemia from aluminum resins in renal failure. Lancet 1970; II: 494-6
76. Rozas VV, Port FK, Rutt WM. Progressive dialysis encephalopathy from dialysate aluminum. Arch Intern Med 1978; 138: 1375-7
77. Griswold WR, Reznik V, Menndoza SA, et al. Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide. Pediatrics 1983; 71: 56-8
78. Russo LS, Beale G, Sandroni S, et al. Aluminum intoxication in undialyzed adults with chronic renal failure. J Neurol Neurosurg Psychiatry 1992; 55: 697-700
79. Salusky ID, Foley J, Nelson P, et al. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and adults with chronic renal disease. N Engl J Med 1991; 324: 527-31
80. Campbell A. The potential role of aluminium in Alzheimer's disease. Nephrol Dial Transplant 2002; 17 Suppl. 2: 17-20
81. Clarkson EM, McDonald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 1966; 30: 425-38
82. Stamatakis MK, Alderman JM, Meyer-Stout PJ. Influence of pH on in vitro disintegration of phosphate binders. Am J Kidney Dis 1998; 32: 808-12
83. Ross EA, Szabo NJ, Tebbett IR. Lead content of calcium supplements. JAMA 2000; 284: 1425-9
84. Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, et al. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol 2002; 42: 1171-6
85. Cushner HM, Copley JB, Lindberg JS, et al. Calcium citrate, a non-aluminum containing phosphate binding agent for treatment of CRF. Kidney Int 1988; 33: 95-9
86. Froment DH, Buddington B, Miller NL, et al. Effect of solubility on the gastrointestinal absorption of aluminum from various aluminum compounds in the rat. J Lab Clin Med 1989; 114: 237-42
87. Froment DP, Molitoris BA, Buddington B, et al. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int 1989; 36: 978-84
88. DeLeacy EA, Cowley DM, Brown JM, et al. Effect of oral citrate on calcium absorption after an oral load of calcium phosphate [letter]. Clin Chem 1989; 35: 1541
89. Pak CYC, Harvey JA, Hsu MC. Enhanced calcium bioavailability from a solubilized form of calcium citrate. J Clin Endocrinol Metab 1987; 65: 801-5
90. Slatopolsky E, Weerts C, Stokes T, et al. Alternative phosphate binders in dialysis patients: calcium carbonate. Semin Nephrol 1986; 6 Suppl. 1: 35-41
91. Salusky IB, Coburn JW, Foley J, et al. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 1986; 108: 767-70
92. Anelli A, Brancaccio D, Damasso R, et al. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis: effects on acidosis, on parathyroid function, and on calcemia. Nephron 1989; 52: 125-32
93. Williams B, Vennegoor M, O'Nunan T, et al. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure. Nephrol Dial Transplant 1989; 4: 725-9
94. Moriniere P, Roussel A, Tahiri Y, et al. Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: disappearance of hyperaluminemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 1982; 19: 784-7
95. Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3: 96-102
96. Andreoli SP, Cunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1978; 9: 206-10
97. Clark AGB, Oner A, Ward G, et al. Safety and efficacy of calcium carbonate in children with chronic real failure. Nephrol Dial Transplant 1989; 4: 539-44
98. Malberti F, Surian M, Poggio F, et al. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis 1988; 12: 487-91
99. Malberti F, Surian M, Colussi G, et al. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder. Kidney Int Suppl 1988; 24: S184-5
100. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphate absorption by phosphorus binders: a theoretical in vitro and in vivo study. J Clin Invest 1989; 83: 66-73
101. Gold CH, Morley JE, Viljoen M, et al. Gastric acid secretion and serum gastrin levels in patients with chronic renal failure on regular hemodialysis. Nephron 1985; 25: 92-5
102. Tan CC, Harden PN, Rodger RS, et al. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant 1996; 11: 851-3
103. Emmett M, Sirmon MD, Kirkpatrick WG, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17: 544-50
104. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998; 22: 569-73
105. Kobrin SM, Godlstein SJ, Shangraw RF, et al. Variable efficacy of calcium carbonate tablets. Am J Kidney Dis 1989: 14: 461-5
106. Mai ML, Emmett M, Sheikh MS, et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36: 690-5
107. Caravaca F, Santos I, Cubero JJ, et al. Calcium acetate versus carbonate as phosphate binders in hemodialysis patients. Nephron 1992; 60: 423-7
108. Pflanz S, Henderson IS, McElduff N, et al. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 1994; 9: 1121-4
109. Schaefer K, Scheer J, Asmus G, et al. The treatment of uraemic hyperphosphatemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991; 6: 170-5
110. Wallot M, Bonzel KE, Winter A, et al. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 1996; 10: 625-30
111. Janssen MJ, van der Kuy A, ter Wee PM, et al. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45: 111-9
112. Sechet A, Hardy P, Hottelart C, et al. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis. Artif Organs 1998; 22: 564-8
113. Moriniere P, Djerad M, Boudailliez B, et al. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate: comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron 1992; 60: 6-11
114. Slatopolsky E, Weesrts C, Norwood K, et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36: 897-903
115. Hutchison AJ, Freemont AJ, Boulton HF, et al. Low-calcium dialysis fluid and oral calcium carbonate in CAPD: a method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7: 1219-25
116. Mactier RA, Van Stone J, Cox A, et al. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987; 28: 222-6
117. Sawyer N, Noonan K, Altmann P, et al. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 105-9
118. Duncan R, Cochrane T, Bhalla C, et al. Low calcium dialysate and hyperparathyroidism. Perit Dial Int 1996; 16 Suppl. 1: S499-502
119. Oettinger CW, Oliver JC, Macon FJ. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients. J Am Soc Nephrol 1992; 3: 995-1001
120. Ben Hamida F, el Esper I, Compagnon M, et al. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron 1993; 63: 258-62
121. Van den Bergh JP, Gelens MA, Klaassen HA, et al. Efficacy and tolerance of three different calcium acetate formulations in hemodialysis patients. Neth J Med 1999; 55: 222-8
122. Gretz N, Zimmermann E, Sellger I, et al. Kalziumverfugbarkeit und Phosphatbindungskapazitat verschiedener Kalziumsalze [abstract]. Klin Wochenschr 1991; 69 Suppl. 23: 170
123. Birck R, Zimmermann E, Wassmer S, et al. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study. Nephrol Dial Transplant 1999; 14: 1475-9
124. Riedel E, Hampl H, Steudle V, et al. Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations. Miner Electrolyte Metab 1996; 22: 119-22
125. Zimmermann E, Wassmer S, Steudle V. Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism. Miner Electrolyte Metab 1996; 22: 196-9
126. Bro S, Rasmussen RA, Handberg J, et al. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis 1998; 31: 257-62
127. Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-6
128. Summerville PJ, Kaye M. Evidence that resistance to the calcemic action of parathyroid hormone in rats with acute uremia is caused by phosphate retention. Kidney Int 1979; 16: 552-60
129. Salusky IB, Ramirez JA, Oppenheim W, et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45: 253-8
130. Parfitt AM. Soft tissue calcification in uremia. Arch Intern Med 1969; 124: 544-56
131. Milliner DS, Zinsmeister AR, Lieberman E, et al. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931-6
132. Velentzas C, Meindok H, Oreopoulos DG, et al. Visceral calcification and the CaXP product. Adv Exp Med Biol 1978; 103: 195-201
133. Goodman WG, Goldin J, Kuzon BD, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83
134. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000; 54: 318-24
135. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Cax PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8
136. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 2003; 14: S310-4
137. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-37
138. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 340-5
139. Holmes-Parley SR, Mandeville WH. Design and characterization of sevelamer hydrochloride: a novel phosphate-binding pharmaceutical. JMS-Pre Appl Chem 1999; A36 (7 and 8): 1085-91
140. Plone MA, Petersen JS, Rosenbaum DP, et al. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002; 41: 517-23
141. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int 2002; 62: 611-09
142. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, et al. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 1997; 12: 961-4
143. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride (RenaGel), a non-calcemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2001; 16: 1870-8
144. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55: 299-307
145. Baxter J, Shimizu F, Takiguchi Y, et al. Effect of iron (III) chitosan intake on the reduction of serum phosphorus in rats. J Pharm Pharmacol 2000; 52: 863-74
146. Palmer RJ, Butenhoff JL, Stevens JB. Cytotoxicity of the rare earth metals cerium, lanthanum, and neodymium in vitro: comparisons with cadmium in a pulmonary macrophage primary culture system. Environ Res 1987; 43: 142-56
147. Joy MS, Hladik G, Finn WF, the Lanthanum Study Group. Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients [abstract]. Presented at the Am Society of Nephrology (ASN) Meeting 1999 Nov: Miami (FL)
148. Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999; 10: 1274-80
149. Weaver CM, Schulze DG, Peck LW, et al. Phosphate-binding capacity of ferrihydrite versus calcium acetate in rats. Am J Kidney Dis 1999; 34: 324-7
150. Gruenhagen SE, Schultze DG, Chansiri G, et al. Effect of sorbitol on the phosphate adsorptive capacity of ferrihydrite suspensions. Pharm Dev Technol 1997; 2 (1): 81-6
151. Zhu H, Webb M, Buckley J, et al. Different Mg to Fe ratios in the mixed metal MgFe hydroxyl-carbonate compounds and the effect on phosphate binding compared with established phosphate binders. J Pharm Sci 2002; 9: 53-66
152. Rankin BJ, Thewles A, Lote CJ, et al. The evaluation of novel mixed metal hydroxyl-carbonates as phosphate binders: an invivo study in the rat. J Pharm Pharmacol 2001; 53: 513-9
153. Spengler K, Follmann H, Boos KS, et al. Cross-linked iron dextran is an efficient oral phosphate binder in rat. Nephrol Dial Transplant 1996; 11: 808-12
154. Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Int 1999; 73 Suppl. 73: S42-5
155. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999; 14: 863-7
156. Burger C, Valcarenghi D, Sandri S, et al. Cross-linking chitosan-Fe (III), an oral phosphate binder: studies in vitro and in vivo. Int J Pharm 2001; 223: 29-33
157. Jing SB, Li L, Ji D, et al. Effect of chitosan on renal function in patients with chronic renal failure. J Pharm Pharmacol 1997; 49: 721-3
158. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 1640-4
159. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71
160. Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303-10
161. Wilkes BM, Reiner D, Kern M, et al. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998; 50: 381-6
162. Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-14
163. Gallieni M, Cozzolino M, Carpani P, et al. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. J Nephrol 2001; 14: 176-83
164. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
165. Chertow GM, Burke SK, Raggi P. Treat to goal working group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52
166. Chertow GM, Goodman WG, Toto RD, et al. In hemodialysis patients, sevelamer (RenaGel) attenuates coronary artery and aortic calcification and reduces LDL-C, APO-B, and HS-CRP compared with calcium acetate (PhosLo) [abstract SA P0603]. Presented at the annual meeting of the American Society of Nephrology; 2002 Nov 1-4: Philadelphia (PA)
167. Walters BA, Delahunty MI, Nabut JL, et al. Reduction in cardiac mortality in hemodialysis patients on sevelamer hydrochloride compared with phosphate binders containing calcium [abstract SU-P0625]. Presented at the annual meeting of the American Society of Nephrology; 2002 Nov 1-4: Philadelphia (PA)
168. Mathur S, Devaraj S, Jialal I. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 2002; 11: 141-7
169. RenaGel prescribing information 2001. Genzyme Corporation, Cambridge (MA)
170. Walters BA, Delahunty MI, Cesiah R, et al. Control of serum phosphate level by sevelamer hydrochloride may occur at the expense of lowering serum bicarbonate in hemodialysis patients [abstract SU-P0577]. Presented at the annual meeting of the American Society of Nephrology; 2002 Nov 1-4: Philadelphia (PA)
171. Gallieni M, Cozolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000; 57: 1776-7
172. Davis JE, Kaplan-Machlis B. Price comparisons between different Pi binders. West Virginia Consult. Available from URL: http://hsc.wvu.edu/consult/ newdrugs/renagel.html [Accessed]
173. Anormed. Currently approved therapeutics for use in hyperphosphataemia and ESRD and market data [online]. Available from URL: http://www.anormed.com/ products/fosrenol/facts_figures.html [Accessed 2003 Oct 22]
174. McIntyre CW, Patel V, Taylor GS, et al. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1643-8
175. Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Clin Nephrol 1999; 51: 18-26
176. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63 [Suppl. 85]: S73-8
177. Graff L, Burnel D. A possible non-aluminum oral phosphate binder? a comparative study on dietary phosphorus absorption. Res Commun Mol Pathol Pharmacol 1995; 89: 373-88
178. Graff L, Burnel D. Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol 1995; 90: 389-401
179. Palasz A, Czekaj P. Toxicological and cytopathological aspects of lanthanides action. Acta Biochim Pol 2000; 47: 1107-14
180. Basu A, Chakrabarty K, Chatterjee GC. Neurotoxicity of lanthanum chloride in newborn chicks. Toxicol Lett 1982; 14: 21-5
181. Briner W, Rycek RF, Moellenberndt A, et al. Neurodevelopmental effects of lanthanum in mice. Neurotoxicol Teratol 2000; 22: 573-81
182. Finn WF, Joy MS, Hladik G, and the Lanthanum Study Group. Results of a dose-ranging placebo-controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis [abstract]. Presented at the American Society of Nephrology (ASN) Meeting 1999 Nov; Miami (FL)
183. Joy MS, Finn WF, and the LAN-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96-107
184. Joy MS, Finn WF, Lanthanum Study Group. Safety profile of lanthanum carbonate in hemodialysis patients: results from a phase III US study [abstract]. Proceedings of the ISN/ASN World Congress of Nephrology 2001 Oct 15, San Francisco (CA)
185. Behets GL, Dams S, Damment PC, et al. An assessment of the effects of lanthanum on bone in a chronic renal failure (CRF) rat model [abstract]. J Am Soc Nephrol 2001; 12: A38
186. Joy MS, Finn WF. Fosrenol™, a novel non-calcium, non-aluminum phosphate binder has a good safety and efficacy profile in the long-term treatment of hyperphosphataemia in hemodialysis patients [abstract SA-P0600], Presented at the annual meeting of the American Society of Nephrology; 2002 Nov 1-4: Philadelphia (PA)
187. Hutchison AJ, Lanthanum Study Group. The novel, non-aluminum, non-calcium phosphate binder, Fosrenol™, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract SA-P0599], Presented at the annual meeting of the American Society of Nephrology; 2002 Nov 1-4: Philadelphia (PA)
188. Fine KD, Santa Ana CA, Porter JL, et al. Intestinal absorption of magnesium from food and supplements. J Clin Invest 1991; 88: 396-402
189. Guillot AP, Hood VL, Runge CF, et al. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 1982; 30 (2): 114-7
190. Oe PL, Lips P, van der Meulen J, et al. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 1987; 28: 180-5
191. Moriniere P, Vinatier I, Westeel PF, et al. Magnesium hydroxide as a complementary aluminum-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralization. Nephrol Dial Transplant 1988; 3: 651-6
192. O'Donovan R, Baldwin D, Hammer M, et al. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1986; I: 880-2
193. Delmez JA, Kelber J, Norwood KY, et al. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49: 163-7
194. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-94
195. Tzanakis I, Pras A, Kounali D, et al. Mitral annular calcification in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 1997; 12: 2036-7
196. Ritz E, Hergesell O. Compounds in development to combat hyperphosphataemia. Expert Opin Investig Drugs 2001; 10: 2185-90
197. Rehm P, Winters J. The effect of ferric chloride utilization on calcium and phosphorus in the animal body. J Nutr 1940; 19: 213-22
198. Brock J, Diamond L. Rickets in rats by iron feeding. J Pediatr 1934; 4: 442-53
199. Okada M, Imamura K, Iida M, et al. Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr 1986; 17: 99-102
200. Spengler K, Follmann H, Boos KS, et al. Characterization and extracorporeal application of a new phosphate-binding agent. Eur J Clin Chem Clin Biochem 1994; 32: 733-9
201. Chang J-M, Hwang S-J, Tsai J-C, et al. Effect of ferric polymaltose complex as a phosphate binder in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1045-7
202. Yamaguchi T, Baxter JG, Maebashi N, et al. Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats. Ren Fail 1999; 21: 453-68
203. Yang W-C, Yang C-S, Hou C-C, et al. An open-label, crossover study of a new phosphate binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002; 17: 265-70
204. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-8
205. Rankin BJ, Zhu H, Webb M, et al. The development and in vitro evaluation of novel mixed metal hydroxyl-carbonate compounds as phosphate binders. J Pharm Pharmacol 2001; 53: 361-9